Improving diagnosis and treatment for the quantified patient
Lead Research Organisation:
King's College London
Department Name: Genetics and Molecular Medicine
Abstract
There are often many alternative prevention and treatment options for common diseases, with varying effectiveness. Key aims of stratified medicine are to identify subgroups of patients for whom similar interventions are likely to be most effective, or who are at high risk of further complications. This project aims to find ways of defining these subgroups and predicting which subgroup any given patient belongs to based on their genetic data, clinical presentation of their disease over time, and the environment they have been exposed to. Psoriasis, an inflammatory skin disease, will be the primary focus of the research but opportunities will be sought to extend the findings to other diseases.
Firstly, existing clinical and genetic patient data will be used to identify genetic differences between patients that respond well and those that do not respond to a relatively new class of psoriasis drugs called biologics. Statistical methods will be developed to determine whether these genetic differences can be combined with previously established clinical measurements to predict which psoriasis patients will respond to each biologic. A "treatment algorithm" (a set of rules to help dermatologists identify the most effective biologic as quickly as possible) will be recommended.
Secondly, the project will seek genetic and environmental/lifestyle factors that put psoriasis patients at risk of progressing to severe disease or developing complications in the form of other diseases ("comorbidities"). This will involve using data from UK Biobank, which comprises 500,000 volunteers from the general UK population. It is known that participants do not always accurately report their health conditions, so an initial challenge will be to accurately determine which participants have psoriasis so that we can study them further. Genetic differences will be examined between participants that have psoriasis and those that do not to refine our understanding of the genetic basis of psoriasis. Subsequently statistical analyses will be performed to identify genetic factors that correspond to (1) severity of psoriasis and (2) risk of comorbidities, and to examine how a patient's environmental exposures contribute to psoriasis risk after accounting for their underlying genetic risk.
Thirdly, the project will examine ways of using artificial intelligence (AI) to automatically analyse patient data and help dermatologists or other healthcare providers to make informed healthcare decisions. For these advanced methods to be effective much larger datasets are needed than are currently available, including regular data on individual patients over time. Relevant types of data could include skin images or descriptive data. New methods of collecting these data will be explored, such as the development of a mobile phone app(lication) to collect data directly from psoriasis patients, and the data infrastructure that would be required to support collection and subsequent AI analysis. It is also proposed to identify existing but currently untapped data resources that can be used to run initial test AI analyses. This could include analysis of image data (e.g. can photographs of psoriasis skin lesions be distinguished from other types of inflammatory skin disease automatically?) or patient-reported "life-quality" data (e.g. can patients that experience a large drop in perceived life quality be predicted at an early stage?).
Finally, opportunities will be sought to collaborate with other research groups so that results and methodology developed during this work can support stratification of other common long-term diseases.
Firstly, existing clinical and genetic patient data will be used to identify genetic differences between patients that respond well and those that do not respond to a relatively new class of psoriasis drugs called biologics. Statistical methods will be developed to determine whether these genetic differences can be combined with previously established clinical measurements to predict which psoriasis patients will respond to each biologic. A "treatment algorithm" (a set of rules to help dermatologists identify the most effective biologic as quickly as possible) will be recommended.
Secondly, the project will seek genetic and environmental/lifestyle factors that put psoriasis patients at risk of progressing to severe disease or developing complications in the form of other diseases ("comorbidities"). This will involve using data from UK Biobank, which comprises 500,000 volunteers from the general UK population. It is known that participants do not always accurately report their health conditions, so an initial challenge will be to accurately determine which participants have psoriasis so that we can study them further. Genetic differences will be examined between participants that have psoriasis and those that do not to refine our understanding of the genetic basis of psoriasis. Subsequently statistical analyses will be performed to identify genetic factors that correspond to (1) severity of psoriasis and (2) risk of comorbidities, and to examine how a patient's environmental exposures contribute to psoriasis risk after accounting for their underlying genetic risk.
Thirdly, the project will examine ways of using artificial intelligence (AI) to automatically analyse patient data and help dermatologists or other healthcare providers to make informed healthcare decisions. For these advanced methods to be effective much larger datasets are needed than are currently available, including regular data on individual patients over time. Relevant types of data could include skin images or descriptive data. New methods of collecting these data will be explored, such as the development of a mobile phone app(lication) to collect data directly from psoriasis patients, and the data infrastructure that would be required to support collection and subsequent AI analysis. It is also proposed to identify existing but currently untapped data resources that can be used to run initial test AI analyses. This could include analysis of image data (e.g. can photographs of psoriasis skin lesions be distinguished from other types of inflammatory skin disease automatically?) or patient-reported "life-quality" data (e.g. can patients that experience a large drop in perceived life quality be predicted at an early stage?).
Finally, opportunities will be sought to collaborate with other research groups so that results and methodology developed during this work can support stratification of other common long-term diseases.
Technical Summary
Stratified approaches to the clinical management of disease promise a substantial public health benefit. The proposed research seeks to identify and validate generalisable stratified approaches, using psoriasis as a model disease, based on unique clinical, genomic and population-scale datasets.
Firstly, using data generated by the Psoriasis Stratification to Optimise Relevant Therapy (PSORT) project, a genome-wide association study will be completed to identify genetic variants robustly associated with response to multiple biologic therapies. A framework will be established to evaluate combined genetic and clinical predictors of response. A treatment algorithm will be recommended and opportunities to validate it locally or via collaboration will be sought.
Secondly, the contribution of genetic and environmental/lifestyle factors to disease course and severity will be investigated. Initial efforts will focus on utilising several established methods to infer and validate psoriasis phenotypes in population-scale datasets such as UK Biobank, including linked electronic health records. Derived data along with PSORT data will be used to refine our understanding of genome-wide psoriasis susceptibility signals via case-control meta-analysis. Genetic and environmental contributions to psoriasis incidence and severity at the population level will be investigated, to include study of gene-environment interaction and comorbidity risk.
Thirdly, artificial intelligence (AI)-based skin disease assessment and management recommendations will be developed. Novel data collection mechanisms will be explored to generate sufficiently large/dense longitudinal datasets; for example, image or text data collected via mobile technology. AI frameworks will be developed and evaluated which use these data to predict when clinical intervention can most effectively reduce disease burden. Pilot analyses will focus on analysis of longitudinal image and patient-reported "life quality" data.
Firstly, using data generated by the Psoriasis Stratification to Optimise Relevant Therapy (PSORT) project, a genome-wide association study will be completed to identify genetic variants robustly associated with response to multiple biologic therapies. A framework will be established to evaluate combined genetic and clinical predictors of response. A treatment algorithm will be recommended and opportunities to validate it locally or via collaboration will be sought.
Secondly, the contribution of genetic and environmental/lifestyle factors to disease course and severity will be investigated. Initial efforts will focus on utilising several established methods to infer and validate psoriasis phenotypes in population-scale datasets such as UK Biobank, including linked electronic health records. Derived data along with PSORT data will be used to refine our understanding of genome-wide psoriasis susceptibility signals via case-control meta-analysis. Genetic and environmental contributions to psoriasis incidence and severity at the population level will be investigated, to include study of gene-environment interaction and comorbidity risk.
Thirdly, artificial intelligence (AI)-based skin disease assessment and management recommendations will be developed. Novel data collection mechanisms will be explored to generate sufficiently large/dense longitudinal datasets; for example, image or text data collected via mobile technology. AI frameworks will be developed and evaluated which use these data to predict when clinical intervention can most effectively reduce disease burden. Pilot analyses will focus on analysis of longitudinal image and patient-reported "life quality" data.
People |
ORCID iD |
Nick Dand (Principal Investigator / Fellow) |
Publications
Andres-Ejarque R
(2021)
Enhanced NF-?B signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis.
in Nature communications
Bechman K
(2022)
Vaccine hesitancy and access to psoriasis care during the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey.
in The British journal of dermatology
Benzian-Olsson N
(2020)
Association of Clinical and Demographic Factors With the Severity of Palmoplantar Pustulosis.
in JAMA dermatology
Corbett M
(2022)
Biomarkers of systemic treatment response in people with psoriasis: a scoping review
in British Journal of Dermatology
Dand N
(2020)
Psoriasis and Genetics.
in Acta dermato-venereologica
Dand N
(2019)
HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis.
in The Journal of allergy and clinical immunology
Dand N
(2023)
GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targets.
in medRxiv : the preprint server for health sciences
Douroudis K
(2022)
Differences in Clinical Features and Comorbid Burden between HLA-C*06:02 Carrier Groups in >9,000 People with Psoriasis
in Journal of Investigative Dermatology
Geifman N
(2021)
Defining trajectories of response in patients with psoriasis treated with biologic therapies.
in The British journal of dermatology
Guideline Title | IPC Statement on COVID-19 and Psoriasis, https://www.psoriasiscouncil.org/blog/COVID-19-Statement.htm |
Description | Shaping recommendations in psoriasis clinical care, International Psoriasis Council |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Citation in clinical guidelines |
Impact | International clinical guideline statement includes: 'Pending results of robust epidemiological studies, emerging data including from registries such as PsoProtect do not appear to provide supportive evidence for a meaningful adverse effect of psoriasis treatments on the risk of acquiring SARS-CoV-2 or of a poorer outcome to COVID-19' |
Guideline Title | National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments, https://www.jaad.org/article/S0190-9622(21)00016-5/fulltext |
Description | Shaping recommendations in psoriasis clinical care, National Psoriasis Foundation COVID-19 Task Force |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Citation in clinical guidelines |
Impact | The following is included in the guidance (ref 20 is our research paper, as above); 'New data confirm that age, male sex, and pre-existing comorbidities are also important drivers of poor COVID-19 outcomes in patients with psoriasis (ref 20)' 'Category 2: What are the effects of psoriasis or PsA treatment on SARS-CoV-2 infection and COVID-19 illness? The evolving literature reaffirms the TF conclusion that treatments for psoriasis and/or PsA do not appear to meaningfully alter the risk of acquiring SARS-CoV-2 infection or having worse COVID-19 outcomes; therefore, patients who are not infected with SARS-CoV-2 should continue their biologic or oral therapies for psoriasis and/or PsA in most cases (guidance 2.1 and 2.2). COVID-19 hospitalization was more frequent in patients using nonbiologic systemic therapy than in those using biologics (OR, 2.8; 95% CI, 1.3-6.2) in a registry of 374 patients with psoriasis from 25 countries (ref 20)' |
Description | BIOMAP |
Amount | € 1,567,007 (EUR) |
Funding ID | 821511 |
Organisation | European Commission H2020 |
Sector | Public |
Country | Belgium |
Start | 04/2019 |
End | 03/2024 |
Description | British Skin Foundation Research Awards |
Amount | £62,000 (GBP) |
Funding ID | 024_F_19 |
Organisation | British Skin Foundation |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | British Skin Foundation Research Awards |
Amount | £79,902 (GBP) |
Funding ID | 042_YI_19 |
Organisation | British Skin Foundation |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 04/2020 |
End | 03/2022 |
Description | Genome-wide meta-analysis and comprehensive functional annotation of susceptibility loci in female frontal fibrosing alopecia (FFA) |
Amount | £9,975 (GBP) |
Organisation | Alopecia UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 12/2020 |
End | 11/2022 |
Title | Monitoring of adalimumab and ustekinumab therapeutic drug levels |
Description | Therapeutic blood levels of of adalimumab and ustekinumab are being currently monitored in clinics to inform doctors on which treatments are most likely to work for each patient, as drug levels 4 weeks into treatment have been shown to predict responce at 12 weeks. The research has been funded by the Psoriasis Association and the PSORT consortium. |
Type | Diagnostic Tool - Non-Imaging |
Current Stage Of Development | Small-scale adoption |
Year Development Stage Completed | 2019 |
Development Status | Under active development/distribution |
Impact | We are now better equipped to identify genetic or other markers that will enable us to give the right medicine to the right patient at the right time. |
Description | 28th EADV Congress - Madrid |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Chair and Speaker for EADV Review and Updates session "Immunopathogenesis, lessons learned from psoriasis" |
Year(s) Of Engagement Activity | 2019 |
Description | 300th meeting of Department of Dermatology and Allergy, Gentofte Hospital, University of Copenhagen |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Professional Practitioners |
Results and Impact | The Department of Dermatology and Allergy, Gentofte Hospital, University of Copenhagen organise one meeting each semester which involve patient demonstrations followed by an invited speaker and a few local talks. The audience is mainly dermatologists in private practice and young dermatologists. The talk lasted for 30 minutes followed by 10 minutes for discussion. The purpose was to provide young dermatologists with new knowledge and clinical data. |
Year(s) Of Engagement Activity | 2019 |
Description | 6th Congress of the Skin Inflammation and Psoriasis International Network (SPIN 2019) |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Speaker for the Plenary Session 1 "Plenary Session 1: Genetics and Pathogenesis in Psoriasis and Atopic Dermatitis", to hold a lecture on the topic "Genetics in psoriasis and atopic dermatitis". |
Year(s) Of Engagement Activity | 2019 |
Description | 6th annual "A Day @ St John's" course |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Postgraduate students |
Results and Impact | informal talk for 20 mins (+ 10 mins for Q&A) on "Inflammatory Dermatoses" aimed at junior doctors and medical students across the country who are keen to pursue a career in dermatology. |
Year(s) Of Engagement Activity | 2019 |
Description | ANNUAL UK DERMATOLOGY COURSE FOR CONSULTANTS 2019 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | The Annual UK Consultants Course is aimed at UK based Consultant Dermatologists in active dermatological practice (who are on the Specialist Register). |
Year(s) Of Engagement Activity | 2019 |
Description | Advanced Medical Dermatology Therapeutics Meeting |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | A two-day meeting with a mixture of plenary talks and case presentations. The audience will be about 80% Consultant Dermatologists from the UK (approx. 150 -200 persons). The meeting will cover a range of dermatological conditions. The focus of the meeting will be on the therapy of the conditions with an emphasis on the complex case. The range of topics covered will bring the attendee up to date with the latest evidence for management of complex medical dermatology and practical guidance on advanced prescribing. |
Year(s) Of Engagement Activity | 2019 |
Description | Advanced Medical Dermatology Therapeutics Meeting |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | "How do newly approved drugs for psoriasis really stack up against older biologics and old favourites?" - chairing the psoriasis session "New therapies vs old " |
Year(s) Of Engagement Activity | 2019 |
Description | Annual UK Dermatology Course for Consultants |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Policymakers/politicians |
Results and Impact | Chaired one of the sessions at the Annual UK Dermatology Course for Consultants |
Year(s) Of Engagement Activity | 2019 |
Description | Biology of the Skin 2019 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Postgraduate students |
Results and Impact | Invitation to speak at annual Introduction to the Biology of the Skin course |
Year(s) Of Engagement Activity | 2019 |
Description | EADV |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | International Psoriasis Council Symposium "Hot topics and challenging cases in psoriasis": facilitiating multiple sessions |
Year(s) Of Engagement Activity | 2019 |
Description | Essential Medical Dermatology Course 2020 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Essential Medical Dermatology is a 3 day course organised by the British Society for Medical Dermatology, aimed at dermatology StRs & Consultants (although Speciality doctors and Associate Specialists are also eligible to attend) who wish to refresh their knowledge of medical dermatology. Expecting 60 delegates to be in attendance. Talk on "How I approach difficult psoriasis" |
Year(s) Of Engagement Activity | 2020 |
Description | IPC Presentation |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Update IPC members on output from major BIOMAP projects (including recent publications), namely: 1. Biomarkers of disease progression scoping review 2. Biomarkers of treatment response scoping review 3. Cross-sectional study examining differences in clinical features and comorbid burden between HLA-C*06:02 subgroups in psoriasis |
Year(s) Of Engagement Activity | 2021 |
Description | IPC Satellite Symposium at 24th World Congress of Dermatology (WCD) in Italy |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | This was an IPC sympsium for members of the IPC to participate in a programme titled "Hot topics and challenging cases in psoriasis: A focus on pustular, biosimilars, pediatrics and treating in under-served areas". A brief discussion took place with each speaker after their lecture and the audience participated in Q&A after the lectures. The second part of the symposium involved challenging cases presented by the faculty and another opportunity for the audience to ask questions. The event was well received and there was an increased interest in related subject areas. |
Year(s) Of Engagement Activity | 2019 |
URL | https://www.psoriasiscouncil.org/agenda_wcd2019.htm |
Description | Internation Psoriasis Council 2019 Think Tank |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Gave lecture on "Therapeutic drug monitoring and personalized dosing of biologics" |
Year(s) Of Engagement Activity | 2019 |
Description | Japanese Society for Investigative Dermatology Meeting (JSID) |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Chair and speaker for IPC symposium |
Year(s) Of Engagement Activity | 2019 |
Description | Lecture on Psoriasis - Department of Dermatology, University of Würzburg, Germany |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Invitation to give a talk on "The evolution of systemic therapy for psoriasis" to students |
Year(s) Of Engagement Activity | 2019 |
Description | New Zealand Dermatological Society Conference |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | A scientific conference only open to fully qualified dermatologists and trainees which takes place annually. The programme consists of dermatologist speakers which sparked questions and discussion afterwards. Feedback indicated an increased interest in subject. |
Year(s) Of Engagement Activity | 2019 |
URL | https://www.nzdsi.org/News/View.aspx?articleid=83848f2e-4c76-4f02-9810-152b19ad5152 |
Description | PSORIASIS WORKSHOP for medical students |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Postgraduate students |
Results and Impact | Talk on "Treatment options in psoriasis (including biologicals)" |
Year(s) Of Engagement Activity | 2020 |
Description | PSORT Consortium Showcase |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Gave talk "Genetic determinants of therapeutic response" |
Year(s) Of Engagement Activity | 2019 |
Description | PSORT Consortium Showcase |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Gave talk "Drug exposure, anti-drug antibodies and treatment response" |
Year(s) Of Engagement Activity | 2019 |
Description | PSORT showcase genetics talk |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Other audiences |
Results and Impact | Presented genetics work as part of the PSORT consortium to a mixed group of stakeholders including patient group representatives. Talk generated questions and discussion of future plans. |
Year(s) Of Engagement Activity | 2019 |
Description | Pleanry Talk, 24th World Congress of Dermatology (WCD) in Italy |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Plenary talk discussing psoriasis which took place at The World Congress of Dermatology, one of the most widely recognised international dermatology meetings. The plenary session involved six speakers which sparked questions and discussion afterwards. Feedback indicated an increased interest in subject. |
Year(s) Of Engagement Activity | 2019 |
URL | https://www.wcd2019milan.org/wcd2019/ |
Description | Preceptorship for Lilly |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Industry/Business |
Results and Impact | Talk on "Treatment approaches". 22 people attending from Lilly: 7 physicians, 4 medical and 11 marketeers, the majority interested in hearing about clinician's perspectives of disease and real world experience. |
Year(s) Of Engagement Activity | 2020 |
Description | Press release and plain language summary for publication in British Journal of Dermatology entitled 'Risk mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey'' |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | We disseminated a plain language summary of our publication in British Journal of Dermatology ('Risk mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey'). This was disseminated (with an accompanying infographic) via Psoriasis Association, IFPA and also the Guy's and St Thomas' NIHR BRC. |
Year(s) Of Engagement Activity | 2021 |
Description | Press release and plain language summary for publication in J Allergy Clin Immunol entitled 'Factors associated with adverse COVID-19 outcomes in patients with psoriasis - insights from a global registry based study' |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | We disseminated a plain language summary for our research publication (and accompanying infographic) to members and supporters of the Psoriasis Association, IFPA and the Guy's and St Thomas' NIHR BRC. |
Year(s) Of Engagement Activity | 2020 |
Description | PsoProtect newsletters |
Form Of Engagement Activity | A magazine, newsletter or online publication |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | We regularly summarise our research outputs in our newsletters, which are emailed to all contributors and partner organisations so that they can disseminate via their networks. We have produced 3 newsletters to date (last in Jan 2021). |
Year(s) Of Engagement Activity | 2020,2021 |
Description | Psoriasis Association 50th Anniversary Annual Conference |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | The annual conference is for members and patients. The purpose of this conference is to raise awareness of Psoriasis with speakers presenting and patients sharing their experiences of living with psoriasis. The conference ended with 'Question time' formed and closing remarks. |
Year(s) Of Engagement Activity | 2019 |
URL | https://www.psoriasis-association.org.uk/awareness/50-for-50-project |
Description | Psoriasis PPI |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | The PPI event was held in the evening of 07-NOV-2019. The meeting was used to discuss local psoriasis research opportunities and treatment options. The PPI event was also used to feedback current research project findings and updates to the attendees. The meeting was also an opportunity for attendees to ask questions of local clinicians and investigators and this was used to help develop future research and treatment strategies. |
Year(s) Of Engagement Activity | 2019 |
Description | Psoriasis from Gene to Clinic JS 2021 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Other audiences |
Results and Impact | Oral presentation by Jake Saklatvala at Psoriasis from Gene to Clinic meeting 2021. The talk described the use of genetic instruments to validate electronic phenotyping for psoriasis in UK Biobank. |
Year(s) Of Engagement Activity | 2021 |
Description | Psoriasis from Gene to Clinic RR 2021 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Other audiences |
Results and Impact | Oral presentation by Ravi Ramessur at Psoriasis from Gene to Clinic meeting 2021. The talk described the epidemiological, anthropometric and clinical differences between psoriasis patients positive or negative for the HLA-C*06:02 allele |
Year(s) Of Engagement Activity | 2021 |
Description | Research presentation Psoriasis from Gene to Clinic |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Other audiences |
Results and Impact | Presenting psoriasis GWAS meta-analysis initial results |
Year(s) Of Engagement Activity | 2021 |
Description | Sharm Derma, Cairo |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Medical conference for Dermatologists consisting of speakers which sparked questions and discussion afterwards. |
Year(s) Of Engagement Activity | 2019 |
Description | Talk at SID 2022 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Presentation on psoriasis genome-wide association study meta-analysis at a leading international annual meeting for investigative dermatologists (clinicians and scientists). |
Year(s) Of Engagement Activity | 2022 |
Description | Talk at SPIN 2022 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | An invited presentation by prerecorded oral talk to the 7th Congress of the Skin Inflammation and Psoriasis International Network, on the subject of biomarkers in psoriasis. This drew on research projects undertaken during the fellowship award and the audience would primarily consist of dermatologists. |
Year(s) Of Engagement Activity | 2022 |
Description | Websites and Social media - PsoProtect and PsoProtectMe |
Form Of Engagement Activity | Engagement focused website, blog or social media channel |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | We set up study websites (psoprotect.org, psoprotectme.org), Twitter (#psoprotect) and Instagram accounts for our psoriasis research project, PsoProtect and PsoProtectMe. Patients and clinicians have engaged well with these platforms - the social media channels have more than 600 followers. We update our social media several times per week with new posts and update the 'Data summary' pages on the PsoProtect and PsoProtectMe websites with summary statistics at the beginning of each month. |
Year(s) Of Engagement Activity | 2020,2021 |
Description | Workshop for Irish healthcare practitioners |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | A workshop designed to Engage, Reflect and Advance Irish HCPs on the current and future practices of Psoriasis. The focus will be initially on treatment goals with the view to discussing ambitions for care to address evolving patient needs in Ireland. This was a 30 min workshop followed by a Q/A session. Feedback suggested a deeper understanding of the current management of psoriasis in terms of treatment goals and the challenges faced by HCPs in achieving higher treatment targets. |
Year(s) Of Engagement Activity | 2019 |